PDCD1 and cancer: Recent preclinical studies using mouse cancer models have demonstrated that COX inhibition enhances immunotherapeutic efficacy of anti-PD-1 therapy28,29, however, suppressive functions of PGE2 in the canine immune system and contributions to cancer immune evasion remain unclear.